AlloVir (ALVR)
(Delayed Data from NSDQ)
$0.62 USD
-0.36 (-36.93%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $0.61 -0.01 (-1.45%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALVR 0.62 -0.36(-36.93%)
Will ALVR be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ALVR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALVR
Are Medical Stocks Lagging AlloVir (ALVR) This Year?
Down -72.39% in 4 Weeks, Here's Why You Should You Buy the Dip in AlloVir, Inc. (ALVR)
ALVR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ALVR
12 Health Care Stocks Moving In Friday's Intraday Session
AlloVir and Kalaris Merge to Advance Retinal Therapies
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
AlloVir falls after all-stock merger deal with Kalaris